Comparative Pharmacology
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus PHENYLBUTAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus PHENYLBUTAZONE.
ADVIL CONGESTION RELIEF vs PHENYLBUTAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.
None Documented
None Documented
Clinical Note
moderatePhenylbutazone + Gatifloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePhenylbutazone + Rosoxacin
"Phenylbutazone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePhenylbutazone + Levofloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePhenylbutazone + Trovafloxacin
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Terminal elimination half-life is 50–65 hours, but exhibits dose-dependent kinetics; can extend to 72–100 hours with repeated dosing or in elderly.
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Primarily hepatic metabolism; renal excretion of metabolites (<1% unchanged). Biliary/fecal excretion accounts for ~20% of total elimination.
Category C
Category C
NSAID/Decongestant Combination
NSAID
"Phenylbutazone may increase the neuroexcitatory activities of Trovafloxacin."